Free Trial

Charles Zhu Analyst Performance

Analyst at Guggenheim

Charles Zhu is a stock analyst at Guggenheim in the medical sector, covering 3 publicly traded companies. Over the past year, Charles Zhu has issued 4 stock ratings, including strong buy, buy, and hold recommendations. While full access to Charles Zhu's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Charles Zhu's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
50.00% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy25.0%1 ratings
Buy25.0%1 ratings
Hold50.0%2 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Charles Zhu at Guggenheim, the majority (50.0%) have been Hold recommendations, followed by 25.0% Strong Buy and 25.0% Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Charles Zhu, an analyst at Guggenheim, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Charles Zhu of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
MED - DRUGS
1 company
33.3%

Charles Zhu's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
10/24/2025Boost Price Target$7.53$12.00Buy
Merus N.V. stock logo
MRUS
Merus
9/30/2025Reiterated Rating$93.67$97.00Market Perform
Merus N.V. stock logo
MRUS
Merus
9/29/2025Downgrade$94.15Hold
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
6/18/2025Upgrade$13.27$22.00Strong-Buy